Epidermal growth factor receptor (EGFR) mutations occur in almost 10–15% of patients affected by non-small cell lung cancer (NSCLC) in the western world and in 30–40% of the Asiatic population [1, 2]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.